To determine the efficacy of a 12-week supervised, hypertrophy-oriented strength training program in preserving skeletal muscle mass, physical function, and quality of life in patients with unresectable pancreatic cancer compared to standard care.
Diagnosis of locally advanced or metastatic unresectable pancreatic cancer
Undergoing chemotherapy or immunotherapy treatment
Age ≥ 18 years
ECOG score ≤ 2
Any relative or absolute contraindication that prevents the performance of training or physical tests.
Diagnosis of other types of primary cancer
Inability to understand Spanish for proper comprehension of the informed consent and questionnaires
Parallel
supervised, hypertrophy-oriented strength training program
Other intervention12-week supervised, hypertrophy-oriented strength training program in preserving skeletal muscle mass
Body Composition
The main objective of this study is to evaluate the effect on body composition (primarily lean mass) through 12 weeks of hypertrophy training in patients with advanced, non-operable pancreatic cancer undergoing treatment
VO2peak
• To analyze whether 12 weeks of hypertrophy training in patients with advanced, unresectable pancreatic cancer receiving chemotherapy and/or immunotherapy has an impact on cardiorespiratory capacity.
Patient-reported outcome measures
• To identify whether 12 weeks of hypertrophy training in patients with advanced, unresectable pancreatic cancer receiving chemotherapy and/or immunotherapy impacts on quality of life. To assess quality of life, the European Organisation for Research and Treatment of Cancer quality of life Questionnaire C30 (EORTC QLQ-C30), version 3.0 will be used. The questionnaire consists of 30 questions grouped into several scales, with higher scores (0-100) indicating better functioning or higher symptom burden.
Anxiety and Depression
• To determine whether 12 weeks of hypertrophy training in patients with advanced, unresectable pancreatic cancer receiving chemotherapy and/or immunotherapy has an impact on anxiety and depression. It will be assesed through the validated questionnaire for assessing anxiety and depression in cancer patients, the Hospital Anxiety and Depression Scale (HADS). It is a 14-item, self-report screening tool used to identify and monitor emotional distress (anxiety and depression) in patients with physical health conditions. It consists of two subscales (7 questions each for anxiety and depression) and is commonly used in hospital settings.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
